Merck & Co., Inc. (MRK) Insider Transactions
Over the last 12 months, 27 Merck & Co., Inc. (MRK) insiders filed 170 SEC Form 4 transactions: $0 in open-market purchases ( 0 distinct buyers) and $72.0M in open-market sales. 0% of all transactions were executed under a pre-scheduled Rule 10b5-1 trading plan.
- $0Open-market buys (1y)
- $72.0MOpen-market sells (1y)
- 27Distinct insiders
- 170Transactions filed
- 0%Under Rule 10b5-1 plan
- 2026-08-13Latest filing
Recent Form 4 Filings Most recent 50 of 170 (1-year window)
Each row is a single Form 4 filing event for MRK, sourced directly from SEC EDGAR. The Type column classifies the SEC transaction code into Buy / Sell / Grant / Exercise / Other; the 10b5-1 badge marks trades executed under a pre-scheduled SEC Rule 10b5-1 plan.
| Date | Insider | Title | Type | SEC Code | Value | Shares | Price |
|---|---|---|---|---|---|---|---|
| 2026-08-13 | Guindo Chirfi | EVP, Access, Policy & Comms | Sell | S | $1.4M | 10,000 | $135.0 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Exercise | M | $4.9M | 41,494 | $117.9 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Exercise | M | $1.1M | 13,433 | $84.7 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Exercise | M | $0 | 41,494 | $0.0 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Exercise | M | $0 | 13,433 | $0.0 |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $1.5M | 11,099 | $131.6 |
| 2026-08-12 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $79.2K | 600 | $132.0 |
| 2026-08-12 | Zachary Jennifer | EVP, General Counsel | Sell | S | $10.7M | 80,315 | $133.5 |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $973.2K | 7,410 | $131.3 |
| 2026-08-11 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $718.3K | 5,427 | $132.3 |
| 2026-08-10 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $2.7M | 20,784 | $130.4 |
| 2026-08-06 | Guindo Chirfi | EVP, Access, Policy & Comms | Sell | S | $2.0M | 15,000 | $131.0 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $105.5K | 805 | $131.0 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $644.0K | 4,945 | $130.2 |
| 2026-08-06 | DeLuca Richard R. | EVP&Pres, Merck Animal Heallth | Sell | S | $39.3K | 300 | $131.0 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $465.3K | 6,311 | $73.7 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $845.7K | 9,709 | $87.1 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $227.5K | 2,686 | $84.7 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $0 | 6,311 | $0.0 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $0 | 9,709 | $0.0 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Exercise | M | $0 | 2,686 | $0.0 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $357.1K | 4,600 | $77.6 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $1.0M | 13,542 | $75.4 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $2.6M | 34,705 | $73.7 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $0 | 4,600 | $0.0 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $0 | 13,542 | $0.0 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Exercise | M | $0 | 34,705 | $0.0 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Sell | S | $812.3K | 6,311 | $128.7 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Sell | S | $1.2M | 9,709 | $128.7 |
| 2026-08-05 | Maraldo David R. | EVP & Pres. MMD | Sell | S | $345.7K | 2,686 | $128.7 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | S | $592.3K | 4,600 | $128.8 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | S | $1.7M | 13,542 | $128.8 |
| 2026-08-05 | Williams David Michael | EVP,Chief Info&Digital Officer | Sell | S | $4.5M | 34,705 | $128.8 |
| 2026-06-30 | Seidman Christine E | – | Grant | A | $8.1K | 63 | $128.5 |
| 2026-06-30 | Karsanbhai Surendralal Lanca | – | Grant | A | $16.2K | 126 | $128.5 |
| 2026-06-30 | Coe Mary Ellen | – | Grant | A | $30.0K | 233 | $128.5 |
| 2026-05-29 | Warden Kathy J | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Karsanbhai Surendralal Lanca | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Coe Mary Ellen | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | THULIN INGE G | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Seidman Christine E | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | RUSSO PATRICIA F | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Rothman Paul | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Mayo Stephen | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | LAVIZZO-MOUREY RISA J | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | GLOCER THOMAS H | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | Craig Pamela J. | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-29 | BAKER DOUGLAS M JR | – | Grant | A | $220.0K | 1,853 | $118.7 |
| 2026-05-05 | Zachary Jennifer | EVP, General Counsel | Grant | A | $0 | 12,064 | $0.0 |
| 2026-05-05 | Zachary Jennifer | EVP, General Counsel | Grant | A | $0 | 35,312 | $0.0 |
Showing the most recent 50 of 170 transactions. For the full 1-year history with sorting, filtering, and cross-ticker industry context, open the full insider transactions drilldown.
Methodology & FAQ
How We Track MRK Insider Transactions
Form 4 disclosures are sourced directly from SEC EDGAR and re-ingested on every pipeline cycle. A complete description of transaction-code handling, the open-market vs grant distinction, and the Rule 10b5-1 plan-reference heuristic is documented in the Methodology.
What is an SEC Form 4 filing for Merck & Co., Inc.?
Form 4 is a transaction-level disclosure that corporate insiders (officers, directors, and beneficial owners of more than 10% of a registered class of equity securities) must file with the SEC within two business days of any change in their beneficial ownership of Merck & Co., Inc. (MRK) shares.
What is a Rule 10b5-1 trading plan?
Rule 10b5-1 is an SEC rule that lets insiders schedule trades in advance under a written plan, providing an affirmative defense against insider-trading allegations as long as the plan was adopted in good faith and not while in possession of material non-public information. Form 4 rows marked "10b5-1" on this page indicate the underlying trade was executed under such a plan; rows without the badge are discretionary or did not reference a plan in the Form 4 footnotes.
How is "insider buying" different from a stock grant or option exercise?
An insider buy (SEC transaction code P) is an open-market purchase of Merck & Co., Inc. (MRK) stock executed at the prevailing market price using the insider's personal capital. Stock grants (code A) and option exercises (code M) are compensation events, not directional trades; they are tracked separately and excluded from the "conviction" signal because they are not discretionary purchases.
How recent is the data?
Form 4 transactions are typically reported within two business days of execution. Pactolio re-ingests the EDGAR feed on a nightly cycle and reflects new filings on the next ingest run, typically within 24 hours of EDGAR acceptance. The table on this page covers the most recent 1-year window.